 Cyclacel Pharmaceuticals, Inc. Nasdaq:CYCC, Nasdaq:CYCCP Cyclacel or the Company, a biopharmaceutical company developing innovative medicines based on cancer biology, announced treatment of the first patient with an oral formulation of CYC065, a CDK29 inhibitor, in part 3 of a Phase 1 study CYC065-01 which is evaluating single agent CYC065 in patients with advanced solid cancers. Parts 1 and 2 of the study are evaluating CYC065 administered as an intravenous infusion. We are excited to report that the first patient has been treated with oral CYC065 in part 3 of our Phase 1 study, said Spiro Rombotis, President and Chief Executive Officer of Cyclacel. 